Investigating how specific mutations in the SF3B1 gene affect cancer development and treatment options.
Official title: Harnessing hotspot specific differences among SF3B1 mutations to define novel mechanisms of tumorigenicity and targetability in solid malignancies
Funded at Vanderbilt University · NIH-10877705 · Data updated 2026-11-12
This study is looking at how certain changes in a gene called SF3B1, which are often found in cancers like breast cancer and leukemia, affect how tumors grow and behave, with the hope of finding better treatments for patients with these types of cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | July 1, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $53,373 |
| NIH project number | 5F30CA268325-02 |
| Project ID | NIH-10877705 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with breast cancer, melanoma, or acute myeloid leukemia who have SF3B1 mutations.
✕Less likely to help
Patients without SF3B1 mutations or those with cancers not associated with this gene may not benefit from this research.
What this research studies
This research focuses on understanding the role of SF3B1 mutations, which are commonly found in various cancers, including breast cancer and acute myeloid leukemia. By using innovative genome editing techniques, the study aims to explore how different SF3B1 mutations influence tumor growth and behavior in cell models. The researchers will analyze changes in gene expression and cancer cell characteristics, such as growth and spread, to identify potential new treatment strategies targeting these mutations. This work could lead to improved therapies for patients with cancers driven by SF3B1 mutations.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with cancers associated with SF3B1 mutations.
How similar studies have gone: Previous research has shown promising results in targeting SF3B1 mutations in acute myeloid leukemia, indicating potential for success in similar approaches for solid tumors.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Bergman, Riley — Vanderbilt University
- Study coordinator: Bergman, Riley
Related research
Other NIH-funded projects on the same topics.
-
Understanding how peer norms around alcohol and HIV prevention affect adolescents and young adults in rural Uganda
This project studies how what young people think their peers do or approve of influences drinking and HIV prevention behaviors in rural Uganda, with the goal of improving health outcomes.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Targeted gene silencing in the brain using siRNA helpers
This grant tests a new way to turn off specific brain genes in particular CNS cell types using siRNA conjugates to help understand brain biology and disease.
-
RSELVES Study: How older couples influence daily life and function with Alzheimer’s risk
A study to understand how daily routines and support between older adults and their partners relate to the development of Alzheimer’s-related functional decline.
-
Molecular mechanisms of coat assembly and regulation in membrane trafficking
A research project seeks to understand how cellular coats organize and regulate the delivery of membrane-bound cargo, with a focus on proteins related to neurological diseases.
-
Synaptic nanostructure in neurodevelopmental disorders
This project aims to map the tiny architecture of brain synapses in native cells to understand how connections form and change in neurodevelopmental disorders.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.